Skip to Main Content

If you were wondering why Novartis (NVS) waited more than three months to notify the Food and Drug Administration about manipulated data for its pricey gene therapy, the answer is … the situation was complicated.

That, anyway, is the message delivered to the agency last month after the crisis erupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED